Moderate-to-Severely Active Crohn's Disease in Patients Naive to Advanced Therapies: What to Do When Higher-Efficacy Advanced Therapy Does Not Achieve Remission

This protocol applies to adults with moderate-to-severely active Crohn's disease who have not yet received advanced therapies. It defines the clinical approach when the preferred first-line strategy — a higher-efficacy advanced therapy — has not achieved the treatment goal.

Clinical Scenario

The patient has moderate-to-severely active CD and is naive to advanced therapies. Current guidelines recommend higher-efficacy advanced therapy as the preferred starting point in this population. When that approach does not achieve sustained remission, a defined next step is warranted.

Prior Treatment — Failure Condition

First-line therapy — target not met

Higher-efficacy advanced therapy — from options including infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, or guselkumab — did not achieve induction and maintenance of clinical remission (CDAI <150). This protocol is the step taken after that failure.

Clinical Target

Induction and maintenance of clinical remission, defined as a Crohn's Disease Activity Index (CDAI) below 150.

Treatment Approach — Partial Overview

Partial overview only — full protocol behind the link below

When higher-efficacy options have not achieved remission, a lower-efficacy advanced therapy is an established alternative in this population. Important regulatory considerations — including jurisdiction-specific guidance for certain drug classes — apply to the selection within this category.

The complete selection criteria, applicable restrictions, and clinical sequencing are available in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

In adult outpatients with moderate-to-severely active CD who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab), rather than a LOWER efficacy medication (certolizumab pegol, upadacitinib).
In the United States, the FDA recommends reserving use of JAK inhibitors in patients with failure or intolerance to TNF-antagonist therapy.
CDAI scores <150 suggest clinical remission, and scores 150–220, 221–450, and >450 denote mild, moderate, and severe disease, respectively.

View source ↗